Gout is a recurrent and painful arthropathy that affects nearly 8 million adults in the United States. 1 About 25% of adults with hypertension have hyperuricemia, and 15% of adults with uncontrolled high blood pressure have gout. 2 Similarly, over half of adults with chronic kidney disease have hyperuricemia, and over 10% have gout. 3 Aside from avoidance of diuretics, 4 there is little evidence to guide practitioners in their choice of antihypertensive agents. In one study, a population-based case-control study, almost all classes of antihypertensive agents were associated with greater risk of gout; the one exception was losartan, which was associated with a lower risk of gout. 5 However, angiotensin-converting enzyme inhibitors (ACEi), despite targeting a similar biologic pathway, were not associated with a lower risk of gout. 5 Thus, we sought to examine the effects of 3 different, but commonly prescribed antihypertensive agents (metoprolol, ramipril, and amlodipine) on uric acid (SUA), gout-related hospitalization, and gout-related medication (GRM) use, using data from the African American Study of Kidney Disease and Hypertension (AASK) trial. We hypothesized that ramipril like losartan would lower SUA given its effects on the renin-angiotensin-aldosterone system.
rate of 20 to 65 ml/min/1.73 m 2 . Persons with diabetes, urine protein-to-creatinine ratio >2.5, secondary hypertension, or heart failure were excluded.
Study design
The AASK study had 2 phases: a trial phase and a subsequent cohort phase. Altogether 1,094 participants were randomized (February 1995 to September 1998) to either intensive blood pressure control (mean arterial pressure < 92 mm Hg) or standard control (mean arterial pressure of 102-107 mm Hg) and to 1 of 3 drug therapies: metoprolol (a sustainedrelease beta blocker), ramipril (an ACEi), or amlodipine (a dihydropyridine calcium-channel blocker). In order to meet blood pressure targets, participants' drug assignments were escalated to the maximum tolerated dose after which other antihypertensive drugs (furosemide, doxazosin, clonidine, and hydralazine or minoxidil) were sequentially added. At the completion of the AASK trial on 30 September 2001, 690 trial participants without end-stage renal disease participated in the cohort study and were given ramipril as their primary antihypertensive therapy. The AASK cohort phase was initiated in April 2002. A detailed assessment of participants' medications was performed during the baseline visit of the AASK cohort.
Our study was limited to the 690 trial participants who enrolled in the AASK cohort after the trial phase in order to examine the effect of drug assignment on GRM use (assessed at baseline of the AASK cohort). We excluded participants who were missing a SUA measurement at either the trial baseline or the 12-month trial visit after the trial baseline (N = 57) as well as participants who had a gout-related hospitalization prior to the trial randomization visit (N = 3). This resulted in a study population of 630 participants.
Outcomes: serum uric acid, gout-related hospitalization, and gout-related medication use SUA was measured in serum collected at the baseline trial visit and at the 12-month follow-up visit after the trial baseline. SUA was quantified using an auto-analyzer in the central laboratory of the data coordinating center (The Cleveland Clinic). 7 Hospitalizations were self-reported and then adjudicated by study staff. ICD9 codes were used to ascertain a goutrelated hospitalization (ICD9 274.XX). We also examined the self-reported GRMs during the baseline cohort visit (2002) (2003) defined as use of at least one of the following: allopurinol, probenecid, or colchicine.
Other covariates
Age and sex were self-reported. Body mass index was determined based on measured height and weight. Systolic and diastolic blood pressure were measured in the seated position in triplicate by trained personnel after 5 minutes of rest. Serum creatinine was measured using standard assays in the central laboratory at The Cleveland Clinic. 7 Diuretic use was assessed at baseline and follow-up visits every 3 months.
Statistical analysis
We used means (SD) and proportions to characterize the cohort population according to medication assignment. Mean SUA according to drug assignment were compared at baseline and 12-months using 2-sided t-tests.
Linear regression models adjusted for blood pressure goal (intensive vs. standard), baseline SUA, baseline diuretic use, and 12-month diuretic use were used to compare the difference in SUA at 12-months between (i) metoprolol vs. ramipril, (ii) ramipril vs. amlodipine, or (iii) metoprolol vs. amlodipine. Cox proportional hazard models were used to examine the association between drug assignment and risk of gout-related hospitalization, adjusted for blood pressure goal (intensive vs. standard), baseline SUA, and diuretic use as a time-varying covariate. Finally, we used logistic regression adjusted for blood pressure goal (intensive vs. standard), baseline SUA, baseline diuretic use, and diuretic use at the start of the AASK cohort to determine the association between drug assignment and odds of GRM use.
A sensitivity analysis was performed using all trial participants with a baseline and 12-month SUA assessment (N = 932). All analyses were conducted with Stata version 14.0 (Stata Corporation, College Station, TX).
RESULTS
The study population had a mean age of 54.9 years (SD, 10.1), and 40% were women. Mean systolic blood pressure was 148.7 (SD, 23.4) mm Hg and mean diastolic blood pressure was 95.1 (SD, 14.0) mm Hg (Supplementary Table S1 ). Mean body mass index was 30.8 (SD, 6.4) kg/m 2 , mean creatinine level was 1.8 (SD, 0.6) mg/dl, and mean SUA was 8.2 (SD, 2.0) mg/dl. In the trial, median follow-up time was 4.7 years. There were a total of 13 hospitalizations that listed gout among its diagnoses; 136 participants reported taking a GRM at the start of the AASK cohort phase.
Metoprolol was associated with a 0.3 (SD, 2.2) mg/ dl increase in SUA at the 12-month visit compared to baseline, while ramipril or amlodipine was not associated with a change in SUA at 12-months from baseline (Table 1) . Furthermore, the 12-month SUA measured in patients assigned metoprolol was significantly greater than both ramipril (0.40 mg/dl; 95% confidence interval: 0.10, 0.70; P = 0.009) and amlodipine (0.57 mg/dl; 0.18, 0.95; P = 0.004). However, there was no difference between ramipril and amlodipine at 12-months (0.17 mg/dl; −0.21, 0.55; P = 0.39). Results were similar when this analysis was repeated among all trial participants with SUA measurements (Supplementary Table S2) .
Being assigned to metoprolol was nonsignificantly associated with a higher risk of having a gout-related hospitalization compared with ramipril (hazard ratio: 3.9; P = 0.09) and significantly associated with a higher odds of GRM use (odds ratio: 1.6; P = 0.04). There was no difference between metoprolol and amlodipine with regards to gout-related hospitalizations (P = 0.93) or GRM use (P = 0.86). Similarly, there was no difference between ramipril and amlodipine with regards to gout-related hospitalizations (P = 0.32) or GRM use (P = 0.14).
DISCUSSION
In this randomized trial of 3 classes of antihypertensive medications in African American adults, we found that being assigned to metoprolol increased SUA over a 12-month period, was associated with higher SUA at 12-months than both ramipril and amlodipine, and was associated with a higher odds of GRM use compared to ramipril. Furthermore, risk of gout-related hospitalizations followed a similar trend, i.e., higher among those assigned metoprolol, despite few events. In addition, we found that while amlodipine lowered SUA compared to metoprolol, it was not associated with a lower risk of gout-related hospitalization or GRM use. These findings suggest that efforts to lower SUA and prevent gout should include avoidance of metoprolol, at least in patients with chronic kidney disease attributed to hypertension.
Hypertension and gout are frequent comorbidities. In fact, 74% of patients with gout have a diagnosis of hypertension. 8 Furthermore, chronic kidney disease is an important risk factor for hyperuricemia and gout. 3 Few studies have evaluated antihypertensive choice and risk of gout. One large case-control study of 74,768 patients from the United Kingdom reported that calcium-channel blockers and losartan were protective against gout, but that beta blockers and ACEi along with diuretics were associated with a higher risk of gout. 5 However, current gout management guidelines only emphasize avoiding diuretics and using losartan for treatment of hypertension in patients with gout. 4 Our study showed that metoprolol increased SUA and risk of GRM use in African American adults. This is consistent with other clinical studies involving beta blockers. One single-blind trial in over 7,000 British adults, the Medical Research Council Treatment Trial for mild hypertension, demonstrated that propranolol significantly increased SUA compared to placebo. 9 However, propranolol was not associated with an increase in incident gout. 9 Similarly, another small, open-label study of 162 hypertensive adults from Denmark showed that atenolol increased SUA by about 0.5 mg/dl compared to baseline. 10 While beta blockers have not been shown to consistently influence SUA excretion, 11 they do increase blood glucose levels, 12, 13 which has been associated with higher SUA. 14, 15 As for mechanisms, it has been hypothesized that excess intracellular glucose is linked with higher SUA production via the pentose phosphate pathway. 16 Compared to metoprolol, amlodipine was associated with a lower SUA at 12-months. This effect has been reported in other trials of calcium-channel blockers. In the ACTION trial, which included 7,665 patients, nifedipine reduced 6-month SUA by 3% compared to placebo. 17 A similar effect was reported in a small trial of 48 hypertensive renal transplant recipients, randomized to either amlodipine or tertatolol for 60 days. 18 In this trial, amlodipine reduced SUA from baseline and increased renal clearance of uric acid, while tertatolol increased SUA from baseline, but had no effect on renal clearance of SUA. However, the difference in clearance was entirely explained by increased filtration rate as the fractional clearance of SUA between groups was identical. 18 This transient increase in glomerular filtration with amlodipine was also observed in the original AASK trial, 6 and is likely related to renal hyperfiltration. Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio. a Difference in 12-month uric acid was determined using linear regression adjusted for blood pressure strategy (intensive vs. standard), baseline uric acid level, baseline diuretic use, and diuretic use at the 12-month visit.
b Hazards of gout-related hospitalization adjusted for blood pressure strategy (intensive vs. standard), baseline uric acid, and diuretic use as a time-varying covariate. Excluding 3 participants with gout-related hospitalizations prior to randomization.
c Odds of gout-related medications were determined via logistic regression adjusted for blood pressure strategy (intensive vs. standard), baseline uric acid level, baseline diuretic use, or diuretic use at the time when gout-related medications were assessed. Gout-related medication use was based on use of allopurinol, probenecid, or colchicine at the baseline visit of the cohort phase of the AASK study, which followed the AASK trial.
Our study suggests that of the 3 medications studied in AASK, ramipril is preferred, at least for lowering SUA and reducing the risk of gout. However, the study was not designed to compare ACEi with angiotensin II receptor blockers, or more specifically, losartan. Nevertheless, our study is useful in reaffirming concerns raised in other studies about beta blockers and SUA or gout and has implications for patients with hypertension.
Our study has limitations. First, the sample size was underpowered to detect a difference in gout-related hospitalizations. Further, there was no formal mechanism for ascertaining or detecting gout flares. Thus, it is possible that these events were underascertained and in some cases misclassified, introducing a conservative bias. Second, we relied on GRMs as a clinical surrogate for gout or its severity after the trial. While allopurinol or probenecid are very specific for SUA reduction, colchicine can be used for other conditions (e.g. pericarditis), although we expect this indication would be rare. Third, urate-lowering therapy influences SUA. Thus, it is possible that participants on urate-lowering therapy would have had even higher SUA during the study. This also serves to bias our SUA comparisons (baseline change and 12-month) toward the null. Finally, our study population was limited to African American adults with nondiabetic kidney disease attributed to hypertension. These exclusions should be considered when applying the results of this study in clinical practice. However, our findings of the effects of beta blockers on uric acid were similar to European trials of predominantly Caucasian participants, making generalizability to other populations, e.g. Hispanic or Asian populations, likely.
Our study also has a number of strengths. African Americans are typically an under-represented population in randomized trials and our study had adequate power to answer our research question. We were able to utilize the high quality and the wellexecuted randomized design of this trial to evaluate the effect of these 3 medications on SUA and gout. Long-term follow-up and medication records during the cohort phase allowed us to look not only at SUA, but also GRM use.
In conclusion, compared to ramipril, metoprolol increased SUA and the risk for GRM use in African American adults. Health professionals treating patients with gout in the setting of chronic kidney disease attributed to hypertension should avoid metoprolol. (M01  RR-00080, M01 RR-00071, M0100032, P20-RR11145, M01  RR00827, M01 RR00052, 2P20 RR11104, RR029887 , and DK 2818-02); by King Pharmaceuticals, which provided monetary support and antihypertensive medications to each clinical center; and by Pfizer, AstraZeneca, GlaxoSmithKline, Forest Laboratories, Pharmacia, and Upjohn, which donated antihypertensive medications. The authors thank the staff and participants of the AASK study for their important contributions.
